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Abstract
Background: In recent years, genetically engineered (GE) mosquitoes have been proposed as a public health
measure against the high incidence of mosquito-borne diseases among the poor in regions of the global South.
While uncertainties as well as risks for humans and ecosystems are entailed by the open-release of GE mosquitoes,
a powerful global health governance non-state organization is funding the development of and advocating the use
of those bio-technologies as public health tools.
In August 2016, the US Food and Drug Agency (FDA) approved the uncaged field trial of a GE Aedes aegypti
mosquito in Key Haven, Florida. The FDA’s decision was based on its assessment of the risks of the proposed
experimental public health research project. The FDA is considered a global regulatory standard setter. So, its
approval of the uncaged field trial could be used by proponents of GE mosquitoes to urge countries in the global
South to permit the use of those bio-technologies.
Method: From a public health ethics perspective, this paper evaluates the FDA’s 2016 risk assessment of the
proposed uncaged field trial of the GE mosquito to determine whether it qualified as a realistic risk evaluation.
Results: The FDA’s risk assessment of the proposed uncaged field trial did not proximate the conditions under
which the GE mosquitoes would be used in regions of the global South where there is a high prevalence of
mosquito-borne diseases.
Conclusion: Given that health and disease have political-economic determinants, whether a risk assessment of a
product is realistic or not particularly matters with respect to interventions meant for public health problems that
disproportionately impact socio-economically marginalized populations. If ineffective public health interventions are
adopted based on risk evaluations that do not closely mirror the conditions under which those products would
actually be used, there could be public health and ethical costs for those populations.
Keywords: Mosquito-borne diseases, Genetically engineered mosquitoes, Risk assessments, Regulatory agencies,
Global health governance, Social determinants of mosquito-borne diseases, Bill and Melinda Gates Foundation,
Global Health Investment Fund, Neoliberal philanthropy
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Background
In recent years, different types of genetically engineered
(GE) mosquitoes have been proposed as public health
measures against the high incidence of mosquito-borne
diseases in regions of the global South. GE mosquitoes
are intended to either change features of or suppress the
population of their wildtype counterpart so that they
cannot act as disease vectors. However, uncertainties as
well as risks for humans and ecosystems are entailed by
the open-release and even uncaged field trials of the GE
mosquitoes (see, for instance, [1–3]). This article provides a public health ethics analysis of the efforts of the
US Food and Drug Administration (FDA) to evaluate
the risks of a proposed (uncaged) field trial in Key
Haven, Florida of the OX513A GE Aedes aegypti
mosquito.1
Specifically, this paper evaluates the FDA’s 2016 Environmental (Risk) Assessment [41] of the proposed open
release experimental project to determine whether it
qualifies as a realistic risk assessment. The criterion of
realistic risk assessment differentiates between risk evaluations that do and those that do not offer relevant information about how a proposed public health tool will
perform under real world conditions. A risk evaluation
of a potential public health measure that does not mirror
the actual conditions under which the product will be
used may have questionable epistemic and public health
value, and thereby, ethical worth. This paper proposes
that the criterion of realistic risk assessment should be
used to evaluate the risk assessments of uncaged field
trials of GE mosquitoes conducted by any regulatory
agency.
The case is made that the FDA’s Environmental (Risk)
Assessment [41] of the proposed uncaged field trial of
the OX513A GE mosquito does not meet the realistic
risk assessment criterion. The field trial site is not an
area where Aedes aegypti-borne diseases are endemic.
So, the uncaged experimental research project would
not provide information about how the OX513A GE Aedes aegypti mosquito would function in regions where
there is a high prevalence of those diseases.
By evaluating the FDA’s Environmental (Risk) Assessment of the proposed uncaged field trial of the OX513A
GE mosquito in Key Haven Florida, this paper means to
ask the larger question why the sponsors of the biotechnology have sought to conduct uncaged field trials
of their patented bio-products in the US. The US does
not have a high incidence of mosquito-borne diseases.
During 2004–2016, four US states had the highest
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reported incidence of mosquito-borne diseases; California had 9254 cases, New York had 7167 cases, Texas
had 6649 cases, and Florida had 3822 cases [4]. To state
the obvious, in the US there is not a significant incidence of mosquito-borne diseases relative to regions of
the global South where mosquito-borne diseases are
endemic.
This paper also analyzes the episodic outbreaks of
dengue, an Aedes aegypti-transmitted infection, in
Puerto Rico. During 2004–2016, the US territory had
80,534 reported cases of mosquito-borne diseases [4]. It
is an instance of the type of real-world conditions under
which there is a (relatively) high incidence of Aedes
aegypti-borne infections and it serves as a telling comparison to the proposed field trial site of Key Haven,
Florida. In Puerto Rico, economic and political factors
play an important role in determining the incidence of
that Aedes aegypti-transmitted infections. So, the question must be asked whether there is ethical warrant for
efforts to use patented high-tech ‘solutions’ that carry
considerable uncertainty and risks for humans and ecosystems to ‘solve’ public health problems that disproportionately affect economically and politically marginalized
populations in regions of the global South.
Additionally, this paper argues that in the interest of
conducting a realistic risk assessment, the FDA should
have evaluated the possible impact of the OX513A GE
Aedes aegypti mosquitoes establishing colonies in areas
with marginalized populations who have limited or no
access to health care.2 The World Health Organization
(WHO) in part classifies mosquito-borne diseases as
neglected diseases because the populations disproportionately affected by them tend to be politically and economically marginalized [5]. Undocumented farmworkers
are discussed as an example of a marginalized population who have limited access to health care in the US
and who could be affected by the uncaged release of GE
mosquitoes. It is argued that the FDA ought to have
considered the possible impact of the uncaged fields trial
of the OX513A GE mosquitoes on them. That possibility
needs to be examined because tetracycline is used in
farms and if the OX513A GE Aedes aegypti mosquitoes
are released near farms (or inadvertently transported to
them) and if they find tetracycline in sufficient quantities
there, the GE mosquitoes might be able to survive over
multiple generations. That could have implications for
undocumented farmworkers who have limited access to
health care.
Next, the justification for this project is discussed. It is
argued that this paper’s evaluation of the FDA’s risk

1

In 2020, the US Environmental Protection Agency authorized
uncaged field trials in Florida and Texas of a different GE mosquito,
i.e., the OX5034 GE Aedes aegypti mosquito [45]. However, evaluating
that agency’s risk assessment of those experimental projects lies
beyond the scope of this paper [45].

2

As mentioned above, this criterion should be used to evaluate the risk
assessment of uncaged field trials of GE mosquitoes conducted by any
regulatory agency.
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assessment of the proposed uncaged field trial matters.
The regulatory agency is considered a global standard
setter. Neoliberal philanthropies that seek to ‘solve’ public health problems of the global South by means of patented high-tech innovations (such as GE mosquitoes)
could use the FDA’s risk assessment to advance their
ends. They could use it to urge other countries to permit
uncaged field trials and use (of different kinds) of GE
mosquitoes in their territories.3 If patented GE mosquitoes get uptake among global health governance actors
as tools for reducing the incidence of mosquito-borne
disease in regions of the global South, it could mean
substantial profits for those who own the patents for
them even though the bio-technologies present significant uncertainties and risks for humans and ecosystems.
Following the discussion of the ‘framing’ of patented
GE mosquitoes as the solution to mosquito-borne diseases in the South, key features of the OX513A GE Aedes aegypti mosquito are outlined. It provides
background information for this paper’s analysis of the
FDA’s Environmental (Risk) Assessment of the uncaged
field trail of the OX513A GE mosquito in Key Haven,
Florida [41].
The FDA’s risk assessment of GE mosquitoes and global
health governance

The socio-political and economic conditions of individuals and groups affects their health and diseases status
[6]. Whether the risk assessments of products conducted
by regulatory agencies approximate actual conditions
under which they will be used especially matters in the
case of products that are intended to act as interventions
for public health problems that disproportionately affect
the poor, such as mosquito-borne diseases. This ethics
analysis argues that if ineffective public health interventions are adopted on the basis of epistemically weak risk
evaluations by regulatory agencies, there could be substantial public health and ethical costs for that
population.
On the international stage, the US FDA is regarded as
a regulatory standard setter, with various countries
adopting its criteria and methods for evaluating pharmaceuticals [7]. So, the FDA’s decision to approve the uncaged field trial of a GE mosquito could have
international significance. Proponents of the GE
3

Arguably, those neoliberal-philanthropies could also use the fact that
the US Environmental Protection Agency (EPA) authorized uncaged
field trials of the OX5034 GE Aedes aegypti mosquito (in Florida and
Texas) to ‘urge’ other countries to permit uncaged field trials and commercial use of GE mosquitoes. However, it is not obvious if the environmental regulatory agency’s risk assessment will carry significant
weight internationally given that in recent years the EPA has come
under the spotlight for serving Monsanto’s interests with respect to its
herbicide Roundup that is intended for use with genetically modified
seed that are tolerant of the chemical (see, for instance, [72], and [73]).
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mosquito could use it to argue that other countries
should permit uncaged field trials of different types of
GE mosquitoes in their territories and employ the same
parameters that the FDA used. This would be a particular concern with respect to low-income countries that
do not have the well-funded and well-resourced regulatory agencies of high-income countries. Regulatory agencies of many countries are under pressure to harmonize
their regulatory approaches. The strongest push to
harmonize comes from the World Trade Organization,
the Organization for Economic Co-operation and Development, and countries that espouse strong patent regimes (see, for instance, [8]).
The FDA’s approval of the OX513A GE Aedes aegypti
mosquito as a public health tool could make it (and
other kinds of patented GE mosquitoes) appealing to the
Global Health Investment Fund and other such social finance enterprises that aim to ‘solve’ the public health
problems of the global South poor by means of patented
products. To understand the normative commitments of
such ventures and their efforts to solve the public health
problems of the global South poor, it is useful to examine their ideological underpinnings. They appear to be a
mix of neoliberalism and neo-colonialism.
Neoliberal-philanthropic enterprises

Neoliberalism does not have a uniform form nor is it
reproduced uniformly over time and contexts [9–11].
Rhetoric that disparages government intervention in the
economy, lobbying for regulations that are pro-corporate
interests, and valorization of the (mythical) bootstrapping, enterprising individual are some of the key practices of neoliberalism. But it is generally understood that
not all of those features are present in each case of neoliberalism and no specific characteristic is common to
all instances of neoliberalism [11].
However, some features do occur in many instantiations of the ideology. The tendency to construe the
democratic state as a moral and practical failure is one
such characteristic of neoliberalism. According to it, the
democratic state is an unfair and inefficient allocator of
social goods and services that discourages individuals
from acting as self-sufficient, enterprising risk takers
[12].
Some powerful non-state actors committed to capitalism or neoliberalism believe they can do better than the
democratic state [13–16]. Thus, they have chosen to take
on some of the roles of the state motivated by the conviction that they can be just, efficient, and effective [14,
16].
However, they are neither chosen by the populations
whose lives they impact to take on those roles nor are
they accountable to them. The lack of accountability
does not seem to be viewed as an ethical or political
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problem by proponents of neoliberalism. So, while the
ideology evinces commitment to the principle of moral
equality of all persons, its norms, policies, and practices
are inconsistent with it. The failure to recognize this inconsistency is an epistemic problem with neoliberalism
that has ethical and political dimensions.
The rise of neoliberalism has also given birth to
neoliberal-philanthropic schemes.4 Those enterprises
aim to assume some of the functions of the state by providing for the needs of the poorer segments of the polity.
They are based on neoliberal business principles and
their proponents appear to see no ethical tension in
serving the interests of their supporters (including funders) as they seek to attend to their philanthropic
mission.5
Social (public health) finance enterprises can be classified as a sub-category of neoliberal philanthropic endeavors.6 While the financially and politically powerful
organizations voluntarily take on some of the roles of
the state, they do not consider themselves accountable
to the populations whose problems they seek to solve
nor are they chosen by them to take on that responsibility [17]. In general, social finance enterprises are predicated on the assumption that charitable giving should
‘work’ for the investors in their organizations by generating profits for them [17].
Neoliberal-philanthropic public health initiatives that
focus on the global South tend to see it from a neocolonial perspective. Mirroring the policies and practices
of colonial public health schemes, they retain for themselves key decision-making power, even as they seek to
solve the public health problems of the South (see, for
instance, [18–20]). They appear to regard state actors
(including national public health agencies) of the global
South as corrupt, inefficient, and ineffective, and themselves as virtuous, effective, and efficient benefactors of
the global South poor. Thus, they tend to retain
decision-making power for themselves [19]. However, it
is an open question whether such enterprises can realize
their ambition of solving the public health problems of
the global South poor, such as the high incidence of
mosquito-borne diseases. In part because that goal may
be at odds with their ambition of producing profits for

Philanthropic ventures, including those that attempted to ‘solve’
public health problems of the global South, predate neoliberalism (see
Birn [18] on the history of the Rockefeller Foundation as a colonialist
capitalist-philanthropical enterprise, also see Packard [46] for a detailed
history and analysis of colonial public health ventures).
5
Based on Birn’s [18] and McGoey’s [15] analysis of the Gates
Foundation, the private philanthropic organization qualifies as a
neoliberal-philanthropic venture.
6
The term ‘social’ in ‘social finance enterprises’ refers to social goods
or programs needed by socio-economically marginalized populations
[17].
4
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their investors or benefitting their funders and supporters [21, 22].7
The Global Health Investment Fund (GHIF) qualifies
as a form of social(public health) finance enterprise.
With the aim of generating profits for its investors,
GHIF invests in patented interventions aimed at solving
public health problems that disproportionately impact
socio-economically marginalized populations in the global South ([23]: S311). In 2014, the Fund’s website stated
that its goal was to help “bring about significant improvements in the treatment and prevention of disease,
and in family planning, and the reduction of maternal
and child mortality (in poorer countries), along with the
prospect of a net financial return for investors” ([24],
quoted in [23]: S311).
Mosquito-borne diseases that disproportionately affect
young children of poor families in regions of the global
South are within the scope of the GHIF’s mission. GE
mosquitoes as a patented public health intervention
could be of considerable interest to GHIF and its investors. For instance, the Oxitec GE mosquito was expected
to cost the Brazilian city of Piracicaba (with a population
of 391,449) an estimated US $1.1 million during a twoyear period at the cost of US $10 per person in the target area (50% of the cost was supposed to financed by
the city’s current mosquito control budget; Oxitec was
expected to cover some part of the cost [25]). As the GE
mosquito is a patented product, presumably it would
have to be re-licensed every season [26]. Another study
suggested that the price of the GE mosquito for use in
an urban area with a population of 50,000 would be an
estimated US $1.9 million in the first year and US
$384,000 each following year [27]. So, if those numbers
are anything to go by, presumably, the patented GE
mosquitoes could bring substantial returns for their
investors.
The initial eleven investors in the GHIF, included the
Bill and Melinda Gates Foundation, JP Morgan Chase,
the World Bank, Merck, Pfizer Foundation, and GlaxoSmithKline ([23]: S311). The possibility that patented GE
mosquitoes could receive the GHIF’s endorsement and
support should not be dismissed out of hand. The Gates
Foundation, a key investor in the GHIF, has funded Target Malaria in the amount of US $75 million [28]. That
initiative is using techniques of modern biotechnology to
develop GE mosquitoes with intentionally altered heritable traits (albeit of a different kind than the OX513A
GE Aedes aegypti mosquito that was proposed for the
uncaged field trial in Key Haven, Florida). Target Malaria aims to use its GE mosquitoes to wipe out malaria
7

Also see Packard [46] on the epistemic problems with the analysis of
public health problems of the global South that such enterprises draw
on.
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in regions of sub-Saharan Africa [28]. A 2016 MIT Technology Review article notes that “[t] he Gates Foundation
has said it no longer believes that malaria can be wiped
out without a (GE mosquito with) gene drive.8 ‘You can’t
walk around with a bed net on you all the time. That’s
not going to eliminate malaria,’ says (Fil) Randazzo (deputy director of the Foundation). With a (GE mosquito
with) gene drive, ‘human behavior change is not required’” [29].
The sentiments of key Gates Foundation personnel
should be taken seriously. The Foundation is a part of
the GHIF and it is a powerful global health governance
actor. It plays a crucial role in deciding which health
care interventions should be adopted and funded for the
poor of low-income countries [13, 30, 31]. As the use of
GE mosquitoes as a public health tool has the support of
a key global health governance actor, and given the credence internationally afforded to the FDA as a regulatory authority, the agency’s risk assessment of the
OX513A GE Aedes aegypti mosquito as a potential public health tool could have a wide-ranging impact. Therefore, this ethics analysis argues that regulatory agencies
have an epistemic, public health, and ethical duty to
adopt a policy of conducting realistic risk assessments of
bio-technologies that are meant to serve as public health
measures. To provide a context for this paper's analysis,
next, key features of mosquito-borne diseases and the
OX513A GE Aedes aegypti mosquito are briefly
described.
The OX513A GE Aedes aegypti mosquito

Mosquito-borne diseases (in conjunction with other
vector-borne diseases) take an enormous toll on the
poor in subtropical and tropical regions. The vulnerability of those populations to vector-borne diseases is partly
determined by a complex of socio-political- economicecological factors, including global warming and capitalled deforestation ([6, 32], vi [13, 33–35]). Histories and
cultures, including the affected population’s stance on
The term ‘(synthetic) gene drive’ generally refers to genetic
modification (by means of techniques of modern biotechnology) that
introduce into organisms intentionally altered heritable traits that are
passed on to the progeny of those organisms at a rate greater than the
one described by Mendel’s law of inheritance [3, 74–77]. The aim of
this type of genetic modification is to affect population-level change in
species by releasing such modified organisms in the wild. When the
modified organisms mate with their wildtype counterparts, their progeny inherit the intentionally altered heritable traits at a rate greater
than the one described by Mendel’s law, and the rate they pass it on to
their offspring is also biased. The OX513A GE Aedes aegypti mosquitoes pass on the intentionally altered heritable traits (that have been
introduced into them) to their progeny at a rate greater than the one
described by Mendel’s law of inheritance ([42]; [41], pgs. 17-18)). However, in the absence of tetracycline in the environment, the modified
mosquitoes and their progeny that inherit the intentionally altered heritable traits are not expected to survive.

8
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risks from mosquitoes, also play a role in determining
their vulnerability (see, for instance, [36]).
However, some proponents of GE mosquitoes construe the disproportionate incidence of those diseases
among the socio-economically marginalized as a primarily, if not wholly, biological phenomenon that must be
solved by means of high-tech interventions (see, for instance, [37]). Their stance is in keeping with a long tradition of certain global health governance actors
biologizing the high incidence of infectious diseases
among the poor of the global South and advocating
purely technical solutions for them [8, 13, 38].
Developed by Oxitec Ltd. (Oxford Insect Technologies), the OX513A GE Aedes aegypti mosquito is meant
to reduce the population of its wild-type counterpart.
The Aedes aegypti mosquito is the main vector of the
yellow fever virus, dengue viruses, chikungunya virus,
and Zika virus [39]. Aedes aegypti mosquitoes are found
in tropical and subtropical regions and tend to establish
their habitats in or near human dwellings. They have
been inadvertently transported around the globe by
humans and Aedes aegypti sub-species are associated
with specific regions [40]. Female Aedes aegypti mosquitoes bite (human and non-human) animals and transmit
organisms that may cause illness; male mosquitoes do
not bite animals ([41], p.16).
The genetic modification of the Oxitec OX513A GE
Aedes aegypti mosquitoes includes a heritable synthetic
genetic sequence that makes them dependent on tetracycline ([41], p.22). It is expected that when male
OX513A GE Aedes aegypti mosquitoes (that are released
in the wild during field trials or open-releases) mate with
their female wildtype counterpart, approximately 95% of
the resulting progeny will inherit the tetracycline dependency trait such that they are not expected to survive
to adulthood in environments that do not have sufficient
amounts of that chemical ([42], p.13). The assumption is
that with periodic releases of additional batches of male
OX513A GE Aedes aegypti mosquitoes, which mate with
their wildtype female counterpart, the population of the
wildtype Aedes aegypti in the target environment will decrease over time because their progeny will not be viable
in environments that do not have tetracycline [41]. That
is expected to result in a decline in the incidence of dengue and other diseases transmitted by that strain of
mosquito.
While Oxitec’s plan was to release only male OX513A
GE Aedes aegypti mosquito during the uncaged field trial
in Key Haven, it estimated that .2% of the released GE
mosquitoes could be females as the sex sorting system
used to differentiate between male and female GE mosquitoes had deficiencies ([42] pg.34). So female GE mosquitoes (with the ability to transmit organisms that
could cause infections in humans) could be accidentally
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released. To get a sense of those percentages, it is useful
to consider the actual number of OX513A GE mosquitoes that would have been released during the proposed
uncaged Key Haven field trial. During the 22 months
long experimental research project, Oxitec anticipated
releasing in the trial site at least 14 million mosquitoes
([41], p.39). That means if the field trial had been conducted, then it was possible that over time approximately 28,704 female GE Aedes aegypti mosquitoes
could have been inadvertently released. If they had found
sufficient tetracycline in the environment, presumably,
they and their GE progeny could have survived, established habitats, and the female GE mosquitoes and the
female GE progeny of female or male GE mosquitoes
could have acted as disease vectors.
Although the uncaged field trial of the OX513A GE
Aedes aegypti mosquito in Key Haven, Florida was
greenlighted by the FDA, it was not conducted because
the local population objected [43]. However, this paper’s
ethics analysis of the FDA’s risk assessment of the proposed field trial matters because, first, it identifies serious shortcomings with the agency’s risk evaluation, and
second, it may have relevance for other proposed
uncaged field trials of GE mosquitoes in various countries including the US. In 2020, two uncaged field trials
in Florida and Texas of a different GE Aedes aegypti
mosquito (OX5034)9 were approved by the US Environmental Protection Agency (EPA).10 An estimated
508,560,000 male OX5034 GE Aedes aegypti mosquito
are to be released as part of uncaged field trials in
Florida, and approximately 249,600,000 male OX5034
GE Aedes aegypti mosquito are to be released in Texas
for an uncaged experimental field research project [44],
p. 5. It is beyond the scope of this paper to address the
question whether the EPA’s risk assessment qualified as
a realistic risk assessment. However, as argued earlier, it
is a criterion by which the EPA’s decision to authorize

9

The OX5034 GE Aedes aegypti mosquito's tetracycline dependency
trait is sex linked such that while it is carried by all GE progeny of the
OX5034 GE Aedes aegypti mosquitoes, the trait is expressed only in
the female OX5034 GE Aedes aegypti organisms [78]).
10
In 2017, Oxitec’s application for the field trial of the OX513A GE
mosquito was transferred to the US EPA. The switch in jurisdiction of
the OX513A GE Aedes aegypti mosquitoes from the FDA to the EPA
occurred because it was decided by the US that regulatory jurisdiction
depends on how applicants classify their products. If a bio-product is
classified by an applicant as a bio-pesticide (rather than a means for
preventing or reducing the incidence of mosquito-borne diseases in
humans), it will be regulated by the EPA and not the FDA [79]. Oxitec
later withdrew its application for the uncaged field trial of the
OX513A GE Aedes aegypti mosquito that it had submitted to the EPA,
and submitted instead to the environmental agency an application for
the uncaged field trials of a different GE mosquito, the OX5034 GE
mosquito. The application for the uncaged field trials of that mosquito
in Florida and Texas was approved by the EPA [78].
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the uncaged field trials of the OX5034 GE mosquito
should be evaluated.

Method
This paper evaluates the FDA’s risk assessment of the
OX513A GE mosquito to determine whether it qualifies
as a realistic risk assessment of the proposed public
health measure.11 The argument is made that regulatory
agencies should have a policy of conducting realistic risk
evaluations of bio-technologies intended to serve as public health tools.12
The concept of realistic risk assessment serves to distinguish between risk evaluations that do and those that
do not provide relevant information about how a proposed public health measure will perform under real
world conditions. A risk assessment of a proposed public
health tool that does not mirror the actual conditions
under which the product will be used may have questionable epistemic and public health value, and thereby,
moral worth.
This paper’s analysis is also informed by the scholarship that examines the efforts of North-based actors to
solve public health problems that disproportionately
affect the poor of the South. The colonial and neoliberal
underpinnings and shape of such public health schemes
have been analyzed at length (see, for instance, [13, 18,
46–49).
Based on that analytic framework, this public health
ethics analysis does four things. First, it identifies some
of the marginalized populations that could be affected
by the uncaged field trials or open-releases of GE mosquitoes. Second, it raises epistemic and ethical questions
11

This paper does not take up the risks or uncertainties with respect to
other animals or ecosystems because it focuses on the public health
risks and uncertainties. However, it must be acknowledged that given
the entangled nature of species and ecosystems, the bracketing of
those concerns is an imperfect heuristic strategy (see [80] for a
critique of such an approach).
12
The US FDA is not the only regulatory agency to have conducted a
risk assessment of uncaged field trials of the OX513A GE mosquito. In
2010–11, Oxitec conducted a release in Malaysia in an uninhabited
forest region, with regulatory authorization. Oxitec also performed
field trials in the Cayman Islands even though the British territory
“had no regulations concerning the release of GM organisms into the
wild” ([81], p.140). The Cayman Island and Malaysian trials were
subject to serious criticism (see [82], p.728). In 2010–2011, a Brazilian
study of the entomological effectiveness of the OX513A GE mosquito
was conducted by Oxitec in conjunction with Brazilian researchers (for
a critical analysis of that project, see [83]). In 2017, the Netherlands’
National Institute for Public Health and the Environment published a
technical evaluation of a proposed release of OX513A Aedes aegypti
mosquitoes on the island of Saba [84]. It did not evaluate the efficacy
of the use of the OX513A GE mosquito or its socio-economic ramifications. Nor did it examine the question of “the desirability of using
these mosquitoes” ([84], Synopsis, p.3). France has also considered the
use of GE mosquitoes. In May 2017, the French High Council for Biotechnology issued a scientific opinion about the use of genetically
modified mosquitoes for vector control (see [85]).
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about risk assessment reports that frame patented, expensive high-tech technological products as easy solutions to complex public health problems, without
acknowledging their socio-political dimensions. Third, it
asks the question whether efforts to solve public health
crises that disproportionately affect the poor should be
influenced by concerns about generating profits for organizations that have invested in particular ‘solutions.’
Fourth, it brings to light the larger issue of whether nonstate actors (with a neoliberal or neoliberal-neo-colonial
worldview) should be making decisions about public
health problems of populations to whom they are not
accountable and who were not chosen by them to make
those decisions for them.
This paper’s ethics analysis stands in contrast to
Meghani and Kuzma’s [50] evaluation of the risk assessment of the proposed field trial of the OX513A GE Aedes aegypti mosquito. That paper examined the risk
evaluation of the proposed field trial that was prepared
by Oxitec, the developer of the OX513A GE mosquito.
This paper does not evaluate Oxitec's Draft Environmental (Risk) Assessment [42], although it should be evaluated using the realistic risk assessment criterion
introduced in this paper. Instead, the FDA’s risk assessment report of the proposed field trial of the OX513A
GE Aedes aegypti mosquito is evaluated on ethical and
epistemic grounds. Moreover, unlike Meghani and
Kuzma [50], this ethics analysis argues that the location
of the proposed field trial means that the FDA would
not be able to generate a realistic assessment of the risks
from the use of the GE insect as a public health tool in
socio-economically marginalized regions with substantial
prevalence of vector-borne diseases.
It should be noted that the FDA’s 2016 Environmental
(Risk) Assessment does not appear to have drawn on the
2014 Guidance Framework for Testing of Genetically
Modified Mosquitoes that has the imprimatur of the
World Health Organization (WHO) and the Foundation
of the National Institute of Health. (Henceforth the document is referred to as the WHO 2014 Guidance.) The
WHO 2014 Guidance [52] is not in the list of references
of the FDA’s 2016 Environmental (Risk) Assessment [41].
As a regulatory agency of a sovereign nation, the FDA is
not obligated to use guidance documents issued by the
WHO, the public health agency of the United Nations.
Sandra Schwindenhammer [51] provides a detailed
critical evaluation of the involvement of Oxitec in shaping the WHO 2014 Guidance [52]. Her analysis in effect
calls into question the epistemic and ethical independence of the WHO 2014 Guidance [52] given Oxitec’s
substantial influence on it. In other words, she can be
read as raising the question whether the document is
biased towards the use of GE mosquitoes and the developers of the patented biotechnology.
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It is also worth considering that the Core Working
Group (that played a significant role in crafting the
WHO 2014 Guidance) included persons who voluntarily
disclosed their professional interest in GM mosquitoes
([52], p.131) and who were or had been affiliated in
some capacity with the Gates Foundation.13 The Gates
Foundation’s role in shaping the project that resulted in
the WHO 2014 Guidance [52] has a long history. It can
be traced back to at least 2009, when it provided funding
support for the development of the guidelines for field
trials of GM mosquitoes [53].
Oxitec and the Gates Foundation have also collaborated,
with the former receiving funding from the latter (see, for
instance, [54]). The significant involvement of Oxitec and
the Gates Foundation in shaping the WHO 2014 Guidance
[52] raises questions about a possible conflict of interest.

Results
A public health ethics evaluation of the FDA’s 2016
environmental (risk) assessment of the proposed uncaged
field trial of the OX513A GE mosquito

This article evaluates the FDA’s 2016 Environmental
(Risk) Assessment report (of the proposed uncaged field
trial) of the OX513A GE Aedes aegypti mosquito. It aims
to determine whether that report provides relevant data
about the safety and efficacy of that GE mosquito as a
public health measure in areas with high incidence of
Aedes aegypti-borne diseases and where tetracycline may
be present in the environment. The question about the
presence of tetracycline in the environment matters because the ability of the OX513A GE Aedes aegypti mosquito to function as a public health tool depends on the
lack of tetracycline in the environment [41]. If tetracycline is present in sufficient quantity, both female and
male OX513A GE Aedes aegypti mosquito would survive, and presumably, the former could act as disease
vectors as could any female progeny of female or male
OX513A GE Aedes aegypti mosquitoes that inherited
the tetracycline dependency trait.
The proposed goals of the uncaged field trial in Key
Haven, Florida included the following ([41], pgs. 16, 9197, 101)):
1. To evaluate whether the OX513A GE Aedes aegypti
mosquitoes would mate successfully with the local
wildtype Aedes aegypti mosquito in the field trial
area and whether the progeny with the heritable
tetracycline trait would survive.
2. To assess whether multiple releases over time of
male OX513A GE mosquitoes would result in a
13

Some of the other persons who were also involved in crafting or
reviewing the WHO 2014 Guidance [52] had direct or indirect
connections to the Gates Foundation too.
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decrease in the population of the wildtype mosquito
population.
3. To determine if the proteins produced by OX513A
GE Aedes aegypti mosquitoes were harmful to
humans and other animals exposed to them ([41],
pgs. 91-7).
4. To ascertain whether the GE Aedes aegypti
mosquito could worsen the public health problem
of dengue and other diseases transmitted by the
Aedes aegypti strain of mosquitoes ([41], pg. 101).
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of real-world conditions under which there is a high incidence of Aedes aegypti-borne infections and it serves
as a telling contrast to the proposed field trial site of Key
Haven, Florida. In Puerto Rico, economic and political
factors play a role in determining the incidence of that
Aedes aegypti-transmitted infections. So, it raises the
question whether there is ethical warrant for efforts to
use a high-tech ‘solution’ that presents considerable uncertainty and risks for humans and ecosystems.

Discussion
Given that the goals of the uncaged field trial of the
GE Aedes aegypti mosquito were to evaluate its safety
for human health, and its ability to not worsen the incidence of Aedes aegypti- borne diseases, like dengue,
under real world conditions (Goal 4), Key Haven was
not the ‘right’ location for the experimental public health
research project. It is a relatively affluent area with no
reported cases of dengue or Zika. So, it would not provide data about whether the OX513A GE mosquito was
effective in reducing Aedes aegypti mosquito transmitted
infections or not worsening them.
It is worth noting that as justification for the proposed
uncaged field trial in Key Haven, the FDA’s Environmental
Assessment cited reported cases of dengue in other parts
of Florida ([41], p.18). In 2009, there were 22 reported
cases of the dengue virus, and in 2010, another 66 reported cases, in addition to other cases in Miami-Dade
and Broward counties and an estimated 1000 people in
the Florida Keys had been exposed to the dengue virus
(approximately 5% of the population) ([41], p.18).
So, arguably, the decision to propose Key Haven as the
site of the (uncaged) field trial of the GE Aedes aegypti
mosquito is as inappropriate as the decision to propose
an area where there is no fire (and virtually no risk of
fire) as the site of the field test of a product that is supposed to prevent fires and act as a fire retardant. In both
cases, arguably, the location of the field trial makes it
unlikely that the project would yield relevant data about
the safety or efficacy of the product under real world
conditions (more on this below).
As mentioned earlier, in 2020, the US EPA authorized
uncaged field trials of the OX5034 GE Aedes aegypti mosquitoes in Florida and Texas [45]. Whether it conducted a
realistic risk assessment of those proposed uncaged field
trials is an important question that lies beyond the scope
of this project, which is limited to the FDA’s risk assessment of the proposed uncaged field trial of the OX513A
GE Aedes aegypti mosquito. However, the EPA’s decision
to authorize the uncaged field trial of the OX5034 GE
mosquito should be evaluated to determine whether it
met the realistic risk assessment criterion.
Next, the periodic outbreaks of dengue in Puerto Rico,
a US territory, are discussed. It is an example of the sort

Dengue in Puerto Rico

The Dengue Branch of the US Centers for Disease Control and Prevention (CDC) is in Puerto Rico. Since 1963
there have been dengue epidemics in Puerto Rico [55,
89]. In non-outbreak years, approximately three to nine
thousand suspected cases have been reported [55]. There
have been five dengue epidemics or outbreaks since
1990 in the US Territory [55, 89] (Table 1).
It is illuminating to contrast the incidence of mosquito-borne diseases in Puerto Rico, Florida, California,
New York, and Texas (see Table 2). In 2016, the year of
the Zika outbreak, Puerto Rico had 35,781 reported
cases of mosquito-borne diseases (primarily Zika) [56].
The high incidence of dengue and Zika in Puerto Rico
is not a matter of chance. Rather it is a telling combination of socio-political-economic-climatic conditions
under which there tends to be significant prevalence of
mosquito-borne diseases. In the US, Puerto Rico has the
highest poverty level relative to that of US states and
other territories, with approximately 45% of its residents
living at or below the federal poverty level ([57], p.1).
The median annual household income in Puerto Rico is
approximately two-thirds less than the US median income ([57], p.1). The contrast between Puerto Rico and
Florida, including Key Haven, reflects that disparity with
respect to the median income (Table 3). Although this is
not a case of apples to apples comparison, it is telling to
an extent.
Presumably, the poverty in Puerto Rico is attributable
in no small part to its political marginalization within
the US political system. It is an unincorporated territory
of the US such that while persons born in Puerto Rico
are American citizens, they cannot vote in presidential
elections (they are permitted to vote in the primary
Table 1 [55, 88]
Year

Reports of suspected dengue cases in Puerto Rico

1994

24,700

1998

17,000

2007

10,508

2010

26,766

2012-13

30,921
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Table 2 (CDC 2018) [4]
State

Reported cases of mosquito-borne diseases during
2004–2016 period

Puerto
Rico

80,534

California

9254

New York

7167

Texas

6649

Florida

3822

elections of political parties). Moreover, the territory
cannot vote in Congress, thus, its political agency and
thereby ability to secure federal resources is severely curtailed, with significant consequences for its population’s
socio-economic and health status [59].
Puerto Rico’s climate in conjunction with its political
marginalization has translated into a recurring pattern of
outbreaks of mosquito-borne diseases. According to a 2016
Natural Resources Committee report on Puerto Rico, “many
public schools, public housing, and even hospitals do not
have air conditioning or proper window screens, leaving
buildings open to mosquitos” [90], p.5. Moreover, approximately half of Puerto Rican homes rely on septic tanks,
“thousands of which were never properly sealed to prevent
mosquitos from breeding” [90], p.5 (see also [60]). The report also noted that there were hundreds of thousands of
unused tires in Puerto Rico ([90], p.5). The tires collect
water, serving as preferred breeding ground of mosquitoes.
(Presumably, the local government did not have the resources to safely dispose of the tires.)
Matysiak & Roess [61] have clarified the complex relationship between climatic, ecologic, and socio-political
factors shaping the periodic emergence of dengue and
the incidence of Zika in Puerto Rico. They have argued
that aside from mosquito population and infection surveillance, the government should provide all residents of
the territory with piped water, regular garbage disposal
service (so that containers, including unused tires, do
not serve as breeding grounds for mosquitoes), and
“convert homes from open sewage to sewer use” ([61],
p.12). The US Centers for Disease Control has noted
that “it was recently found that Ae. (i.e., Aedes) aegypti
(mosquito) is able to undergo immature development in
broken or open septic tanks in Puerto Rico, resulting in
Table 3 (US Census Bureau [58])
State/city

Median household income (in 2017
dollars) during the 2013–2017 period

Puerto Rico

$ 19,775

Florida

$ 50,883

Key Haven (Coconut
Creek city), Florida

$ 56,556
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the production of hundreds or thousands of Ae. aegypti
(mosquito) adults per day” [62].
So, in contrast to US states, the US territory of Puerto
Rico has an urgent need for socio-political and economic
interventions to reduce the incidence of dengue and
Zika. This analysis of the socio-political and economic
components of the outbreaks of Aedes aegypti-borne diseases in Puerto Rico raises questions about the ethical
warrant of proposals to use GE mosquitoes to reduce
the incidence of those infections in socio-economically
marginalized regions.
Criteria for a realistic risk assessment of the OX513A GE
mosquito

For the sake of a realistic risk assessment of the uncaged
field trial of the OX513 GE mosquito as a public health
tool to reduce the high incidence of Aedes aegypti
borne-diseases, the experimental project would have to
be proposed for a location that met at least two conditions. First, the field trial area would have to approximate circumstances under which Aedes aegypti
transmitted diseases are endemic. In other words, it
would have to be sited at a location where a number of
persons might have Aedes aegypti transmitted viruses.
That would allow for a meaningful assessment of the
possibility of (inadvertently released) female GE Aedes
aegypti mosquitoes or female GE progeny (of female or
male GE mosquitoes) acquiring viruses when they feed
on infected persons and transmitting them to others.
A risk assessment that reckoned with that possibility
would have to include a detailed plan to track infections in
humans that were attributable to (any inadvertently released) female GE Aedes aegypti mosquitoes or any female
GE progeny of male or female GE mosquitoes. It would
also track the interaction between the GE mosquito transmitted infections and other infections common in that
population. This is an ethical requirement and good research practice. In fact, it is standard practice for the FDA
to require report of adverse events during trials of pharmaceutical and medical devices products. So, it stands to reason that the same standard should be applied to these biotechnologies that are meant to act as a public health tool
against mosquito-borne diseases. Moreover, any regulatory
agency that authorizes the uncaged field trials or use of GE
mosquitoes should require reports of adverse events attributable to the bio-products they regulate.
The other criterion for a realistic risk assessment of
the OX513A GE mosquito would have to contend with
the very real possibility of tetracycline in the environment. In the US and a number of other countries, tetracycline, an antibiotic, is overused for human therapeutic
purposes. In 2018, in the US, it also constituted the
largest volume of medically important antimicrobials
sold or distributed for livestock (3,974,179 kg) and,
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during 2017–18, the chemical’s use increased by 12%
([63], p.3).
One of the ways in which tetracycline enters the environment is as waste from pharmaceutical manufacturing.
Waste from pharmaceutical manufacturing facilities
“contain 10–1000 times higher pharmaceuticals concentrations than other wastewaters … ” [64].14 In fact, various kinds of antibiotics have been found in untreated
wastewater in many parts of the world (see, for instance,
the review article by Daghrir and Drogui [65] on the ubiquity and persistence of tetracycline in aquatic and terrestrial environments; also see [66].
Given the widespread inappropriate use of antibiotics
in animal feed for prophylactic purposes [67] and given
the use of tetracycline on fruit farms, it is possible that
there might be tetracycline in the untreated wastewater
of farms. The presence of tetracycline could allow the
tetracycline dependent OX513A GE mosquitoes to survive and establish colonies (see, for instance, [68]). So, a
realistic risk assessment of the OX513A GE Aedes
aegypti mosquito would factor in the possibility of tetracycline in the environment.
Risks to marginalized populations: a public health and
ethical issue

It is unlikely that the uncaged field trial in Key Haven
would provide information about whether the modified
mosquitoes could establish colonies under real world
circumstances where tetracycline use is common and
considerable. The FDA’s Environmental Assessment of
the proposed uncaged field trial in Key Haven stated that
in so many words: [A]quaculture facilities, farms, hospitals, or municipal sewage facilities are the only sources
that theoretically could introduce into the environment
sufficiently high levels of tetracycline to allow survival of
OX513A (GE mosquito) progeny in the environment …
(but there are) … no farms, including aquaculture facilities or citrus groves, or hospitals/medical centers in the
proposed trial site” ([41], p.112).
In the interest of conducting a realistic risk assessment, the FDA ought to have assessed the possible impact of the OX513A GE Aedes aegypti mosquitoes
establishing colonies in regions with marginalized populations. As mentioned earlier, the World Health
Organization in part classifies mosquito-borne diseases
as neglected diseases because the populations disproportionately affected by them in tropical and sub-tropical
A 2014 Caribbean Business article identified Puerto Rico as the “fifth
largest area in the world for pharmaceutical manufacturing with more
than 80 (manufacturing) plants …” [86]. It is not known whether
tetracycline is manufactured in Puerto Rico, but the capacity of
wastewater treatment facilities to treat effluent from pharmaceutical
facilities has been a serious ongoing public health and environmental
concern for the territory (see, for instance, [87]).
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regions tend to be politically and economically marginalized (see, [5]). Farmworkers who have limited access to
health care qualify as an example of a marginalized
population in the US that could be affected by the uncaged release of GE mosquitoes. It is argued that the
FDA ought to have considered the possible impact of
the uncaged fields trials of the OX513A GE mosquitoes
on them.15
If the OX513A GE Aedes aegypti mosquitoes are released near farms (or inadvertently transported to them)
and if they find tetracycline in sufficient quantities there,
they might be able to survive over multiple generations.
In the interest of conducting a realistic risk assessment,
the FDA should have considered what that would mean
for farmworkers who have limited access to health care.
That worry, presumably, may have underlain the May
13, 2016 comment submitted to the FDA by Friends of
Earth [69]. The civil society organization submitted a
detailed letter in response to the FDA’s request for public
comments on the February 2016 Draft Environmental
Assessment report for the OX513A GE Aedes aegypti mosquito (the draft risk assessment was prepared by Oxitec
[42]). Among other things, the civil society organization
noted that the EPA was considering permitting increased
use of tetracycline in Florida as a pesticide in citrus farms
and if that request was approved by the EPA and if the
OX513A GE mosquitoes were (inadvertently) transported
to those farms, the GE mosquitoes could establish habitats
in those locations [69]. Tetracycline is commonly used in
agriculture and that, earlier in 2016, on behalf of citrus
growers, the Florida Department of Agriculture and
Consumer Services had requested the EPA’s permission to
increase the use of tetracycline in citrus farms to control
the bacteria that causes Citrus Greening disease (Docket
No. EPA-HQ-OPP-2015-0849-0001). The civil society
organization expressed the worry that if the EPA permitted increased use of tetracycline in agriculture in Florida,
then hundreds of thousands of pounds of the chemical
would be spread on citrus farmlands, obviating “the lethal
trait in the GE mosquitoes and their offspring could survive and continue to breed” [69].
In 2016, there were no citrus farms in Key Haven (the
proposed field trial site). However, according to the
United States Department of Agriculture's National
Agricultural Statistics Service, in 2015–16, a total of
737,800 acres in the US were devoted to citrus crops
(737,800), with 435,300 acres (58.9%) in Florida ([91],
p.8).

14

15

This section clarifies why the establishment of OX513A GE Aedes
aegypti mosquito colonies is a concern with respect to farms.
However, it does not mean that other areas where tetracycline might
be in the environment (such as locations where wastewater from
pharmaceutical facilities is discharged, aquaculture facilities, hospitals,
or municipal sewage facilities) are not a cause of concern.
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Citrus crop harvesting is labor intensive. As each fruit
must be picked by hand, citrus farms employ significant
numbers of farmworkers. If the OX513A GE Aedes
aegypti mosquitoes were inadvertently transported to or
areas near those farms and established habitats there,
farmworkers could be exposed to them. As mentioned
earlier, given that tetracycline is also used in the US on
livestock farms for prophylactic and therapeutic purposes [63], the FDA’s risk assessment should have contended with the possibility of the OX513A GE Aedes
aegypti mosquito establishing in those areas and its significance for farmworkers and their families, a socio-economically marginalized population.
Farmworkers generally live close to the lands on which
they work. In a 2017 report, the National Farm Worker
Ministry has noted that substandard housing is a reality
and worry for farmworkers [70]. Low wages for farmworkers and inadequate and fragmented social protection programs mean that many farmworkers have to live
in crowded, unsanitary housing that “often lack basic
utilities, (and are in) … isolated areas far away from important services like health clinics ...” [70].
Farm owners in the US rely on undocumented
workers to do labor intensive work that citizens or permanent residents are unwilling to take on, such as harvesting fruits and vegetables, and milking cows. The US
Department of Agriculture estimated that during the
2012–14 period, approximately 47% of crop farmworkers
were unauthorized persons [71]. 16Those farmworkers
and their children are more likely than documented
farmworkers to live in substandard housing because of
their irregular immigration status [70]. The US limits
undocumented persons’ access to publicly funded health
care because of their irregular immigration status. If GE
mosquitoes establish habitats near farm fields where
tetracycline is used, farmworkers and their families (including those who are undocumented) could be exposed
to them. Their limited access to health care could compound the risk to them.
The FDA’s Environmental Assessment did not consider the risk to farm laborers (including those who are
undocumented and their families which may include
young children) from the establishment of habitats of
the OX513A GE Aedes aegypti mosquito in citrus farms
and other kinds of farms where tetracycline is used in
significant amounts and where climatic conditions are
suitable for that strain of mosquitoes. That omission is
ethically and politically significant and it results in a risk
assessment that is epistemically weak. Specifically, it
does not provide realistic data about the safety and efficacy of the GE mosquito in regions with marginalized
16

According to a 2010 Southern Poverty Law Center report, 6 out of
10 farmworkers were undocumented ([88], p.4).
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populations at risk of mosquito-borne diseases and
where tetracycline may be present in sufficient quantities
in the environment.
The FDA may have been trying to minimize the risk
from the uncaged field trial of the OX513A GE Aedes
aegypti mosquito by authorizing it for Key Haven, Florida. It is a location where Aedes aegypti mosquito-borne
diseases are non-existent and there is low probability of
tetracycline in the environment so that even if female
GE mosquitoes were inadvertently released during the
experimental field research project, it was unlikely that
they would survive and act as diseases vectors, and GE
mosquitoes would establish colonies in or near that area.
However, the authorization of Key Haven as the site of
proposed uncaged field trial is a double-edged sword because it means that the risk assessment does not provide
relevant data about the safety and efficacy of GE mosquitoes in real world conditions. From an ethics perspective, it does not qualify as a realistic risk assessment of
the proposed public health tool.
Whether the FDA’s risk assessment is realistic or not
matters because the regulatory agency is an international
regulatory standard setter, and the Gates Foundation, a
key global health governance actor, has espoused GE
mosquitoes as the solution to the high incidence of
mosquito-borne diseases in regions of the global South.
The agency’s risk assessment of the GE mosquito could
be (mis)read as indicating that the bio-technology can be
used as a safe and efficacious public health tool against
mosquito-borne diseases, including in regions of low
and lower middle-income countries where mosquitoborne diseases are a significant public health problem
and where tetracycline may be in the environment. That
could motivate GHIF and other such social (public
health) finance enterprises to push for the use of GE
mosquitoes in regions of the global South where
mosquito-borne diseases disproportionately affect the
poor. To prevent such (mis)readings, there is an epistemic, public health, and ethical imperative on regulatory agencies to adopt a policy of conducting realistic
risk assessments of proposed (uncaged) field trials of GE
mosquitoes.

Conclusion
This paper evaluated the FDA’s 2016 Environmental Assessment report of a proposed uncaged field trial of the
OX513A GE mosquito. It was argued that the risk assessment report prepared by the regulatory agency did
not qualify as a realistic assessment because the uncaged field trial was proposed for an area that did
not proximate the real-world conditions under which
the OX513 GE Aedes aegypti mosquito would be used
to try to reduce Aedes aegypti transmitted infections.
The FDA may have authorized the experimental bio-
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technology research project at such a site so as to
substantially reduce the risks from the field trial.
However, it also meant that the risk assessment of
such a field trial would not provide an accurate
evaluation of the risks from the use of the OX513A
GE Aedes aegypti mosquito in regions where there is
a high incidence of Aedes aegypti transmitted infections in the population.
This ethics analysis identified some of the marginalized populations that could be affected by the uncaged
field trials of GE mosquitoes as well as open-release of
those bio-technologies. It also raised questions about the
epistemic and ethical value of risk assessment reports
that present patented, expensive high-tech biotechnologies as simple solutions to complex multidimensional public health problems that disproportionately affect the global South poor. In addition, it asked
the question whether non-state actors (with a neoliberal
or neoliberal-neo-colonial orientation) should be making
decisions about public health problems of populations to
whom they are not accountable and who were not
chosen by them to make those decisions for them.
By evaluating the FDA’s risk assessment of the proposed uncaged field trial in Key Haven, Florida and by
identifying the low-incidence of mosquito-borne diseases
in the states of the US, this paper raised the question
why the sponsors of the bio-technology seek to conduct
uncaged field trials in the US. It was argued that proponents of the biotechnologies may be interested in using
the fact that a US regulatory agency authorized the uncaged field trials of GE mosquitoes to urge other countries to permit uncaged field trials and commercial use
of the patented bio-technologies.
Another key aim of this paper has been to argue that
given that health and disease have political-economic determinants, whether a risk assessment of a product is
realistic or not particularly matters with respect to interventions meant for public health problems that primarily
impact socio-economically marginalized populations. If
ineffective interventions are adopted based on risk evaluations that do not approximate conditions under which
the product would actually be used, there could be public health and ethical costs for those populations.
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